BIOLASE (NASDAQ:BIOL) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of BIOLASE (NASDAQ:BIOL) in a research report released on Wednesday. The brokerage issued a sell rating on the medical technology company’s stock.

Separately, Benchmark reaffirmed a “speculative buy” rating and set a $0.40 price target on shares of BIOLASE in a research report on Wednesday, October 2nd.

BIOLASE Stock Up 1.2 %

Shares of NASDAQ:BIOL opened at $0.01 on Wednesday. The company has a market capitalization of $290,640.90, a price-to-earnings ratio of 0.00 and a beta of 0.67. BIOLASE has a 52 week low of $0.02 and a 52 week high of $1.94. The firm has a 50 day moving average of $0.01 and a 200 day moving average of $0.03.

About BIOLASE

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.